Nemtabrutinib + Ibrutinib + Acalabrutinib

Phase 3Recruiting

0 views this week 0 watching⚡ Active🧬Featured in Oncology Pipeline Watch

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Lymphocytic Leukemia

Conditions

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Trial Timeline

Dec 13, 2023 → Sep 7, 2032

NCT ID

NCT06136559

About Nemtabrutinib + Ibrutinib + Acalabrutinib

Nemtabrutinib + Ibrutinib + Acalabrutinib is a phase 3 stage product being developed by Merck for Chronic Lymphocytic Leukemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06136559. Target conditions include Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Lymphocytic Leukemia were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06136559	Phase 3	Recruiting	Dec 13, 2023	Sep 7, 2032	Chronic Lymphocytic Leukemia

Competing Products

20 competing products in Chronic Lymphocytic Leukemia

See all competitors

Product	Company	Stage	Hype Score
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25
LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2)	Lyra Therapeutics	Phase 2	25
480 Mometasone Furoate Sinus Drug Depot	Lyra Therapeutics	Phase 1	19
LYR-210 + Sham procedure control	Lyra Therapeutics	Phase 3	30